Park Place Capital Corp Sells 60 Shares of Danaher Co. (NYSE:DHR)

Park Place Capital Corp decreased its position in Danaher Co. (NYSE:DHR) by 4.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,220 shares of the conglomerate’s stock after selling 60 shares during the period. Park Place Capital Corp’s holdings in Danaher were worth $305,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Cape Investment Advisory Inc. bought a new stake in shares of Danaher during the 4th quarter valued at about $25,000. Tsfg LLC grew its stake in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. Wetzel Investment Advisors Inc. bought a new stake in shares of Danaher during the 4th quarter valued at about $29,000. Redmont Wealth Advisors LLC bought a new stake in shares of Danaher during the 1st quarter valued at about $30,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Danaher during the 4th quarter valued at about $36,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 19,085 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total transaction of $4,866,675.00. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $29,578,725. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Rainer Blair sold 19,085 shares of Danaher stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $255.00, for a total value of $4,866,675.00. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at $29,578,725. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 113,174 shares of company stock worth $29,775,644. 11.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. Citigroup lifted their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. SVB Leerink boosted their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $276.88.

Danaher Stock Performance

Danaher stock traded down $7.13 during midday trading on Monday, hitting $269.62. 1,399,745 shares of the company were exchanged, compared to its average volume of 2,902,743. The firm has a market capitalization of $194.72 billion, a PE ratio of 46.91, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The business has a fifty day simple moving average of $256.29 and a two-hundred day simple moving average of $251.12. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the company earned $2.05 earnings per share. Danaher’s quarterly revenue was down 2.9% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, July 26th. Stockholders of record on Friday, June 28th were given a $0.27 dividend. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.